Dilafor Signs Supply and Partnership Agreement with Opocrin

Dilafor AB and Opocrin S.p.A. have announced that they have entered into a commercial supply and partnership agreement. In the agreement, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for Dilafor's candidate drug tafoxiparin for the European, US, CIS and Japanese markets.

Furthermore, Opocrin will supply manufacturing services during clinical development of tafoxiparin and the companies will jointly develop the commercial manufacturing of tafoxiparin.

Opocrin is one of the most experienced European manufacturers of polysaccharides, such as low molecular weight heparins. Dilafor is a Karolinska Development portfolio company.

The partnership will initially focus on the clinical supply of tafoxiparin in support of the Phase II and Phase III clinical trial program in obstetrical indications. Opocrin will support the company with services and manufacturing needed to take tafoxiparin through those clinical studies and by preparing for the commercial supply of tafoxiparin for major markets such as US, EU, Japan and CIS.

Further details on the investment and the terms of the agreement are not being disclosed.

“We are looking forward working together with Opocrin in this exciting and important phase in the development of tafoxiparin. Opocrin has extensive experience in the manufacturing of polysaccharide derivatives such as tafoxiparin making them an excellent commercial partner for Dilafor” says Lena Degling Wikingsson, CEO at Dilafor AB.

"We are excited to work with Dilafor and to support them as manufacturing partner of tafoxiparin. The candidate drug addresses important medical needs and has potential to improve delivery which leads to better fetal and maternal health", says Giulia Falcone, Managing Director of Opocrin S.p.A.